IRVINE, Calif., April 09, 2026 (GLOBE NEWSWIRE)-- Cloudbreak Pharma Inc., (HKEX 2592), a clinical stage ophthalmic drug company leveraging its proprietary Multi Kinase Inhibitor (MKI) discovery ...
This achievement represents a significant milestone in this development program and positions Cloudbreak to deliver top-line 12-month efficacy data in the third quarter of 2026. Topline data, if ...
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
According to a survey of volunteers for the ongoing phase 3 trial of Cloudbreak Pharma's lead candidate, a treatment for the disease known as "surfer's eye," more than three-quarters of respondents ...
Milestone achievement advances potential first FDA-approved disease-modifying therapy for pterygium, a condition affecting just under one billion people globally, including 15 million people in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results